MD Communications Group
  • Home
  • Services
  • Areas of Expertise
  • Qualifications
  • Clients
  • Contact

         Psychiatry/Neurology

                               At a glance...
 Psychiatry
  • Depression, ADHD, schizophrenia, anxiety, alcohol dependence, schizoaffective disorder, pharmacogenomics, adherence issues, managed  care
  • Selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, dual-acting antidepressants, tricyclic antidepressants, atypical antipsychotics, serotonin/dopamine antagonists, methylphenidate, benzodiazepines, depot agents

 Neurology
  • Parkinson’s disease, multiple sclerosis, monoamine oxidase B inhibitors, copaxone, L-dopa

 
Psychiatry

“Development and psychometric evaluation of a clinical global impression scale for schizoaffective disorder” (instrument validation article)

“A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder” (clinical trial)

“Adherence to pharmacotherapy in patients with alcohol and opioid addiction” (review)

“Strategies for effective management of depression in primary care” (managed care supplement article)

“Clinical pharmacology of antidepressants” (managed care supplement article)

“Collaborative care models for the treatment of depression” (managed care supplement article)

“Clinical considerations of depression” (managed care supplement article)

“An evaluation of the steady state and single-dose pharmacokinetics of medisorb naltrexone in healthy subjects” (clinical trial)

“Human pharmacology and abuse potential of methylphenidate transdermal system” (clinical trial)

“Association between a Polymorphism in the ciliary neurotrophic factor (CNTF) gene and response to iloperidone treatment in patients with schizophrenia” (subanalysis of clinical trial)

Safety and efficacy of the selegiline transdermal system in children with attention deficit hyperactivity disorder with or without Tourette’s syndrome” (referenced, annotated outline)

“Antidepressants: differential pharmacology and new pathways” (referenced, annotated outline)

“Interactions between iloperidone and ketoconazole in healthy subjects: a two-period, open-label pharmacokinetic study” (referenced, annotated outline)

“Pharmacokinetic interactions between iloperidone and fluoxetine:  an open-label, single-sequence, crossover study in healthy subjects” (referenced, annotated outline)

CME monograph—Common Problems in Diagnosis and Treatment of Schizophrenia

Monograph on panic disorder (treatment section)

Sales training modules for an MAOI antidepressant


Neurology

7 scientific exhibit posters for levetiracetam (antiepileptic)

“The natural history of primary progressive multiple sclerosis: what we think we know”(review)

Branded slide kit for Copaxone

“Istradefylline (KW-6002) as adjunctive therapy in patients with advanced Parkinson’s disease: a positive safety profile with supporting efficacy” (poster)

Disease state and therapy training backgrounders for Parkinson’s disease

Back to Areas of Expertise
phone/fax: (760) 448-6668 | email:[email protected]